280 related articles for article (PubMed ID: 34482771)
1. 2021 ASCO genitourinary cancers symposium: a focus on renal cell carcinoma.
Iacovelli R; Cannella MA; Ciccarese C; Astore S; Foschi N; Palermo G; Tortora G
Expert Rev Anticancer Ther; 2021 Nov; 21(11):1203-1206. PubMed ID: 34482771
[TBL] [Abstract][Full Text] [Related]
2. 2023 ASCO genitourinary cancers symposium: focus on renal cell carcinoma.
Anghelone A; Strusi A; Scala A; Panebianco M; Ciccarese C; Iacovelli R
Expert Rev Anticancer Ther; 2023 Jul; 23(7):669-672. PubMed ID: 37246571
[TBL] [Abstract][Full Text] [Related]
3. LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma.
Choueiri TK; Powles T; Voss MH; Plimack ER; Gurney H; Song Y; Perini RF; Rodriguez-Lopez K; Rini BI
Future Oncol; 2023 Dec; 19(40):2631-2640. PubMed ID: 37882432
[TBL] [Abstract][Full Text] [Related]
4. Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors.
Iacovelli R; Ciccarese C; Bria E; Bracarda S; Porta C; Procopio G; Tortora G
Eur J Cancer; 2020 Sep; 136():195-203. PubMed ID: 32712550
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab plus lenvatinib for radically unresectable or metastatic renal cell carcinoma in the Japanese population.
Fujiwara R; Yuasa T; Kobayashi K; Yoshida T; Kageyama S
Expert Rev Anticancer Ther; 2023 May; 23(5):461-469. PubMed ID: 37038721
[TBL] [Abstract][Full Text] [Related]
6. Inside the 2015 ASCO Genitourinary Cancers Symposium.
Santoni M; Massari F; Iacovelli R; Ciccarese C; Verri E; Burattini L; Montironi R; Nolè F; Tortora G; Cascinu S
Future Oncol; 2015; 11(13):1859-62. PubMed ID: 26161923
[TBL] [Abstract][Full Text] [Related]
7. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
Shah AY; Kotecha RR; Lemke EA; Chandramohan A; Chaim JL; Msaouel P; Xiao L; Gao J; Campbell MT; Zurita AJ; Wang J; Corn PG; Jonasch E; Motzer RJ; Sharma P; Voss MH; Tannir NM
Eur J Cancer; 2019 Jun; 114():67-75. PubMed ID: 31075726
[TBL] [Abstract][Full Text] [Related]
9. Combining Immune Checkpoint and VEGFR Inhibition in Favorable Risk and Elderly Patients With Metastatic Renal Cell Carcinoma.
Varkaris A; Xu W; Davis RB; Healy B; McDermott DF
Clin Genitourin Cancer; 2020 Jun; 18(3):179-184.e3. PubMed ID: 32144046
[TBL] [Abstract][Full Text] [Related]
10. LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy.
Motzer RJ; Schmidinger M; Eto M; Suarez C; Figlin R; Liu Y; Perini R; Zhang Y; Heng DY
Future Oncol; 2023 Jan; 19(2):113-121. PubMed ID: 36752726
[TBL] [Abstract][Full Text] [Related]
11. Lenvatinib plus pembrolizumab combination therapy for adult patients with advanced renal cell carcinoma.
Ged Y; Lee CH
Expert Rev Anticancer Ther; 2022 Oct; 22(10):1049-1059. PubMed ID: 36154355
[TBL] [Abstract][Full Text] [Related]
12. Optimal management of metastatic renal cell carcinoma: current status.
Escudier B; Albiges L; Sonpavde G
Drugs; 2013 Apr; 73(5):427-38. PubMed ID: 23572408
[TBL] [Abstract][Full Text] [Related]
13. Selected news from the 2014 Genitourinary Cancers Symposium: translating novel strategies into clinical practice.
Bianconi M; Santoni M; Massari F; Faloppi L; Del Prete M; Giampieri R; Ciccarese C; Modena A; Tortora G; Scartozzi M; Cascinu S
Future Oncol; 2014 Nov; 10(14):2103-6. PubMed ID: 25471023
[TBL] [Abstract][Full Text] [Related]
14. The Efficacy of Lenvatinib Plus Everolimus in Patients with Metastatic Renal Cell Carcinoma Exhibiting Primary Resistance to Front-Line Targeted Therapy or Immunotherapy.
Hamieh L; Beck RL; Le VH; Hsieh JJ
Clin Genitourin Cancer; 2020 Aug; 18(4):252-257.e2. PubMed ID: 32291161
[TBL] [Abstract][Full Text] [Related]
15. First-line immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma with sarcomatoid features.
Fontes-Sousa M; Calvo E
Cancer Treat Rev; 2022 Apr; 105():102374. PubMed ID: 35303549
[TBL] [Abstract][Full Text] [Related]
16. Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline.
Rathmell WK; Rumble RB; Van Veldhuizen PJ; Al-Ahmadie H; Emamekhoo H; Hauke RJ; Louie AV; Milowsky MI; Molina AM; Rose TL; Siva S; Zaorsky NG; Zhang T; Qamar R; Kungel TM; Lewis B; Singer EA
J Clin Oncol; 2022 Sep; 40(25):2957-2995. PubMed ID: 35728020
[TBL] [Abstract][Full Text] [Related]
17. Biomarker-Oriented Therapy in Bladder and Renal Cancer.
Scholtes MP; Alberts AR; Iflé IG; Verhagen PCMS; van der Veldt AAM; Zuiverloon TCM
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799514
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab for the treatment of renal cell carcinoma.
Di Bona C; Stühler V; Rausch S; Stenzl A; Bedke J
Expert Opin Biol Ther; 2021 Sep; 21(9):1157-1164. PubMed ID: 34042015
[TBL] [Abstract][Full Text] [Related]
19. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit.
Oudard S; Elaidi RT
Cancer Treat Rev; 2012 Dec; 38(8):981-7. PubMed ID: 22289686
[TBL] [Abstract][Full Text] [Related]
20. The roaring 2020s: a new decade of systemic therapy for renal cell carcinoma.
Srivastava A; Doppalapudi SK; Patel HV; Srinivasan R; Singer EA
Curr Opin Oncol; 2022 May; 34(3):234-242. PubMed ID: 35266906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
